Literature DB >> 15386470

Large-scale molecular dynamics simulations of HLA-A*0201 complexed with a tumor-specific antigenic peptide: can the alpha3 and beta2m domains be neglected?

Shunzhou Wan1, Peter Coveney, Darren R Flower.   

Abstract

Large-scale massively parallel molecular dynamics (MD) simulations of the human class I major histocompatibility complex (MHC) protein HLA-A*0201 bound to a decameric tumor-specific antigenic peptide GVYDGREHTV were performed using a scalable MD code on high-performance computing platforms. Such computational capabilities put us in reach of simulations of various scales and complexities. The supercomputing resources available for this study allow us to compare directly differences in the behavior of very large molecular models; in this case, the entire extracellular portion of the peptide-MHC complex vs. the isolated peptide binding domain. Comparison of the results from the partial and the whole system simulations indicates that the peptide is less tightly bound in the partial system than in the whole system. From a detailed study of conformations, solvent-accessible surface area, the nature of the water network structure, and the binding energies, we conclude that, when considering the conformation of the alpha1-alpha2 domain, the alpha3 and beta2m domains cannot be neglected. Copyright 2004 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15386470     DOI: 10.1002/jcc.20100

Source DB:  PubMed          Journal:  J Comput Chem        ISSN: 0192-8651            Impact factor:   3.376


  11 in total

Review 1.  Modelling biological complexity: a physical scientist's perspective.

Authors:  Peter V Coveney; Philip W Fowler
Journal:  J R Soc Interface       Date:  2005-09-22       Impact factor: 4.118

2.  A critical cross-validation of high throughput structural binding prediction methods for pMHC.

Authors:  Bernhard Knapp; Ulrich Omasits; Sophie Frantal; Wolfgang Schreiner
Journal:  J Comput Aided Mol Des       Date:  2009-02-05       Impact factor: 3.686

3.  Side chain substitution benchmark for peptide/MHC interaction.

Authors:  Bernhard Knapp; Ulrich Omasits; Wolfgang Schreiner
Journal:  Protein Sci       Date:  2008-04-23       Impact factor: 6.725

4.  HLA-DP2 binding prediction by molecular dynamics simulations.

Authors:  Irini Doytchinova; Peicho Petkov; Ivan Dimitrov; Mariyana Atanasova; Darren R Flower
Journal:  Protein Sci       Date:  2011-09-27       Impact factor: 6.725

5.  NMR spectroscopy reveals unexpected structural variation at the protein-protein interface in MHC class I molecules.

Authors:  Monika Beerbaum; Martin Ballaschk; Natalja Erdmann; Christina Schnick; Anne Diehl; Barbara Uchanska-Ziegler; Andreas Ziegler; Peter Schmieder
Journal:  J Biomol NMR       Date:  2013-09-05       Impact factor: 2.835

6.  Predicting peptide vaccine candidates against H1N1 influenza virus through theoretical approaches.

Authors:  Martiniano Bello; Rafael Campos-Rodriguez; Saul Rojas-Hernandez; Arturo Contis-Montes de Oca; José Correa-Basurto
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

7.  T-cell epitope prediction and immune complex simulation using molecular dynamics: state of the art and persisting challenges.

Authors:  Matthew N Davies; Darren R Flower; Kanchan Phadwal; Isabel K Macdonald; Peter V Coveney; Shunzhou Wan
Journal:  Immunome Res       Date:  2010-11-03

8.  Peptide binding prediction for the human class II MHC allele HLA-DP2: a molecular docking approach.

Authors:  Atanas Patronov; Ivan Dimitrov; Darren R Flower; Irini Doytchinova
Journal:  BMC Struct Biol       Date:  2011-07-14

9.  Molecular dynamics simulations to provide insights into epitopes coupled to the soluble and membrane-bound MHC-II complexes.

Authors:  Martiniano Bello; Jose Correa-Basurto
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

10.  Early relaxation dynamics in the LC 13 T cell receptor in reaction to 172 altered peptide ligands: a molecular dynamics simulation study.

Authors:  Bernhard Knapp; Georg Dorffner; Wolfgang Schreiner
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.